Furthermore, treatment with chemotherapy in SLFN12-overexpressing TNBC cells resulted in differential responses in SLFN12 signature cancer genes—providing further insight into targeted treatment options for TNBC patients, as demonstrated in Table 1. Here, SLFN12 is linked to cancer.